Ozmosi | HS-20089 Drug Profile

Product Description

HS-20089 is being developed by Shanghai Hansoh Biomedical for the treatment of advanced solid tumor. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05263479?term=HS-20089&draw=2&rank=1)

Mechanisms of Action: B7-H4 Inhibitor

Novel Mechanism: Yes

Modality: Antibody Drug Conjugate

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Hansoh Pharma
Company Location: Asia Pacific
Company Founding Year: 1995
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for HS-20089

Countries in Clinic: China

Active Clinical Trial Count: 7

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Ovarian Cancer

Phase 2: Endometrial Cancer|Fallopian Tube Cancer|Peritoneal Cancer

Phase 1: Oncology Solid Tumor Unspecified

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success	Latest Trial Update Date	Data Updated
NCT06336707	HS-20089-103	P1	Recruiting	Oncology Solid Tumor Unspecified	2026-04-08	21%	2024-07-19	Primary Endpoints\|Start Date
NCT06014190	HS-20089-201	P2	Recruiting	Fallopian Tube Cancer\|Endometrial Cancer\|Ovarian Cancer\|Peritoneal Cancer	2025-12-31	44%	2024-04-04
CTR20241023	CTR20241023	P1	Recruiting	Oncology Solid Tumor Unspecified	None		2025-04-29	Patient Enrollment\|Start Date\|Treatments\|Trial Status
CTR20232465	CTR20232465	P2	Recruiting	Ovarian Cancer\|Endometrial Cancer	None		2025-04-29	Patient Enrollment\|Start Date\|Treatments\|Trial Status
NCT06855069	HS-20089-301	P3	Recruiting	Ovarian Cancer	2027-03-07	25%	2025-12-18	Primary Endpoints\|Start Date\|Treatments\|Trial Status
CTR20212906	CTR20212906	P1	Recruiting	Oncology Solid Tumor Unspecified	None		2025-04-29	Patient Enrollment\|Start Date\|Treatments\|Trial Status
NCT05263479	HS-20089-101	P1	Recruiting	Oncology Solid Tumor Unspecified	2024-12-31	21%	2024-04-04

Recent News Events

Date	Type	Title
01/01/2024	News Article	GSK and Hansoh Pharma's Innovative Partnership in Cancer Treatment

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

HS-20089

Alternative Names: hs-20089, hs 20089, hs20089 Clinical Status: Active Latest Update: 2025-12-17 Latest Update Note: Clinical Trial Update